Aadi Bioscience Inc. (Aadi) is a biopharmaceutical company focused on precision therapies for genetically-defined cancers.
We strive to unleash the potential of mTOR inhibition by employing precision medicine & nanoparticle technology to bring transformational therapies to cancer patients with mTOR pathway driver alterations. Our lead product has been FDA-approved for the treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumors (PEComa).
In March 2025, we became a wholly-owned subsidiary of KAKEN Pharmaceutical Co., Ltd., an R&D driven pharmaceutical company in Japan. A science-first mindset and patient-centric approach is always in our genes. Together with KAKEN, we continue to dedicate to developing products for cancers with mTOR pathway driver alterations.
For more information, please visit: https://aadibio.com/ and https://www.kaken.co.jp/english/.
Company Details
- Employees
- 50
- Founded
- -
- Address
- 2 Headquarters Plz, East Tower
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://aadibio.com/
- HQ
- Morristown, New Jersey
Aadi Bioscience, Inc Questions
Aadi Bioscience, Inc's website is https://aadibio.com/
Aadi Bioscience, Inc's LinkedIn profile is https://www.linkedin.com/company/aadi-bioscience-inc
Aadi Bioscience, Inc has
50 employees.
View email and phone details for 50
employees at Aadi Bioscience, Inc.
Aadi Bioscience, Inc's industry is
Biotechnology Research
Aadi Bioscience, Inc's top competitors are
Nuvation Bio,
Enplusone Biosciences,
Whitehawk Therapeutics,
Abcuro, Inc,
Sera Prognostics,
Lykos Therapeutics,
Virocell Biologics,
Subsense Inc.,
Garuda Therapeutics,
Sernova.
Aadi Bioscience, Inc's categories are Biotechnology Research
Aadi Bioscience, Inc's founding year is 2011
